期刊
TRENDS IN BIOTECHNOLOGY
卷 33, 期 5, 页码 253-258出版社
CELL PRESS
DOI: 10.1016/j.tibtech.2015.02.007
关键词
protein nanoparticles; drug delivery; biomaterials; biomimetics; protein engineering; targeted therapy
资金
- Fund for Health of Spain (FIS) [PI12/00327, PI12/01861]
- La Marato de TV3 [TV32013-133930, TV32013-132031, 416/C/2013]
- MINECO [BIO2013-41019-P]
- Centro de Investigacion Biomedica en Red (GIBER) de Bioingenieria, Biomateriales y Nanomedicina (NANOPROTHER project) - Instituto de Salud Carlos III
- European Regional Development Fund
- Instituto de Salud Carlos III (ISCIII)
- Centro de Investigacion Biomedica en Red (GIBER) de Bioingenieria, Biomateriales y Nanomedicina (NANOCOMETS project) - Instituto de Salud Carlos III
High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or 'artificial viruses'. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting 'smart' functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug-protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据